389 related articles for article (PubMed ID: 19923864)
1. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
3. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
5. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Suwattee P; Chow S; Berg BC; Warshaw EM
Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
[No Abstract] [Full Text] [Related]
7. Interstitial granulomatous drug reaction to sorafenib.
Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
[No Abstract] [Full Text] [Related]
8. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
9. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
10. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
11. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
12. [Hand-foot syndrome and sorafenib].
Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
14. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
[TBL] [Abstract][Full Text] [Related]
15. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
[TBL] [Abstract][Full Text] [Related]
16. [Palmoplantar cutaneous reaction to sorafenib].
Echeverría B; Llombart B; Botella-Estrada R; Guillén C
Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
[No Abstract] [Full Text] [Related]
17. Sunitinib-induced hand-foot syndrome: a new, distinct form.
Fife DJ; Wu JJ; Behnam SE; Linden KG
Clin Exp Dermatol; 2010 Mar; 35(2):200-1. PubMed ID: 19486049
[No Abstract] [Full Text] [Related]
18. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
19. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Jain L; Gardner ER; Figg WD; Chernick MS; Kong HH
Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
[TBL] [Abstract][Full Text] [Related]
20. [Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome].
Delgado-Téllez L; Campos Fernández de Sevilla MA; Tutau F
Farm Hosp; 2009; 33(5):288-9. PubMed ID: 19775581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
